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Abstract
The ABL protein-tyrosine kinase regulates intracellular signaling pathways controlling
diverse cellular processes and contributes to several forms of cancer. The kinase activity of
ABL is repressed by intramolecular interactions involving its regulatory Ncap, SH3 and SH2
domains. Small molecules that allosterically regulate ABL kinase activity through its non-
catalytic domains may represent selective probes of ABL function. Here we report a screen-
ing assay for chemical modulators of ABL kinase activity that target the regulatory interac-
tion of the SH3 domain with the SH2-kinase linker. This fluorescence polarization (FP)
assay is based on a purified recombinant ABL protein consisting of the N-cap, SH3 and
SH2 domains plus the SH2-kinase linker (N32L protein) and a short fluorescein-labeled
probe peptide that binds to the SH3 domain. In assay development experiments, we found
that the probe peptide binds to the recombinant ABL N32L protein in vitro, producing a
robust FP signal that can be competed with an excess of unlabeled peptide. The FP signal
is not observed with control N32L proteins bearing either an inactivating mutation in the
SH3 domain or enhanced SH3:linker interaction. A pilot screen of 1200 FDA-approved
drugs identified four compounds that specifically reduced the FP signal by at least three
standard deviations from the untreated controls. Secondary assays showed that one of
these hit compounds, the antithrombotic drug dipyridamole, enhances ABL kinase activity
in vitro to a greater extent than the previously described ABL agonist, DPH. Docking studies
predicted that this compound binds to a pocket formed at the interface of the SH3 domain
and the linker, suggesting that it activates ABL by disrupting this regulatory interaction.
These results show that screening assays based on the non-catalytic domains of ABL can
identify allosteric small molecule regulators of kinase function, providing a new approach to
selective drug discovery for this important kinase system.
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Introduction
The ABL protein-tyrosine kinase plays diverse roles in the regulation of cell proliferation, sur-
vival, adhesion, migration and the genotoxic stress response [1–3]. ABL kinase activity is per-
haps best known in the context of BCR-ABL, the translocation gene product responsible for
chronic myelogenous leukemia (CML) and some forms of acute lymphocytic leukemia [4,5].
The clinical management of CML has been revolutionized by selective ATP-competitive inhibi-
tors of BCR-ABL, of which imatinib is the prototype [6]. However, chronic use of kinase inhib-
itors often leads to drug resistance due to selection for mutations that disrupt drug binding or
allosterically influence the conformation of the drug binding pocket [7].
The growing problem of imatininb resistance in BCR-ABL has fueled efforts to identify
compounds that work outside of the kinase active site. Such compounds offer advantages in
terms of enhanced specificity, because they have the potential to exploit non-conserved regula-
tory features unique to ABL that persist to some extent in BCR-ABL as well [8]. The kinase
activity of ABL is tightly regulated in vivo by an auto-inhibitory mechanism. The ABL ‘core’
region, which includes a myristoylated N-terminal ‘cap’ (N-cap), SH3 and SH2 domains, an
SH2-kinase linker and the kinase domain, is both necessary and sufficient for ABL auto-inhibi-
tion [9]. Subsequent X-ray crystal structures of the ABL core revealed three critical intramolec-
ular interactions that regulate kinase activity [10–12] (Fig 1A and 1B). First, the SH2-kinase
linker forms a polyproline type II helix that binds to the SH3 domain, forming an interface
between the SH3 domain and the N-lobe of the kinase domain. Second, the SH2 domain inter-
acts with the back of the kinase domain C-lobe through an extensive network of hydrogen
bonds. Aromatic interactions between the side chains of SH2 Tyr158 and kinase domain
Tyr361 also help to stabilize this interaction (see Panjarian et al. for an explanation of the ABL
amino acid numbering scheme [13]). Finally, the myristoylated N-cap binds a deep hydropho-
bic pocket in the C-lobe of the kinase domain, clamping the SH3 and SH2 domains against the
back of the kinase domain. Small molecules that occupy the myristic acid binding site in the C-
lobe of the kinase domain have proven to be effective allosteric inhibitors of BCR-ABL function
[14,15].
Mutational analysis demonstrates that intramolecular SH3:linker interaction plays a central
role in ABL auto-inhibition. Substitution of linker proline residues at positions 242 and 249
with glutamate disrupts SH3:linker interaction, resulting in ABL kinase activation [16]. In con-
trast, increasing the proline content of the linker enhances internal SH3 binding and over-
comes the activating effects of mutations in the myristic acid binding pocket as well as the
kinase domain gatekeeper residue (Thr315) [8]. Remarkably, enhanced SH3:linker interaction
also dramatically sensitizes BCR-ABL-transformed cells to inhibition by both imatinib and the
allosteric inhibitor, GNF-2, which binds to the myristic acid binding pocket [8]. These findings
suggest that small molecules enhancing or disrupting this natural regulatory mechanism may
represent selective allosteric modulators of ABL kinase activity.
In contrast to the tremendous research efforts invested in discovering inhibitors for ABL
kinase activity, few studies have explored the discovery of small molecules that activate ABL.
Selective agonists may represent useful probes to examine the role of ABL kinase activity in
normal cellular functions, such as DNA-damage repair pathways. ABL is activated in response
to multiple forms of genotoxic stress and interacts with modulators of both DNA damage-
induced apoptosis (e.g. p73) and DNA repair (e.g. Rad51), resulting in cell death or survival
depending on the cellular environment [2]. Moreover, recent studies have shown that ABL
inhibits the growth of breast cancer xenografts and promotes the phenotypic reversion of inva-
sive breast cancer cells [17,18]. Selective and potent agonists would provide a new approach to
explore these and other biological roles of ABL in vivo.
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Fig 1. FP assay for small moleculemodulators of ABL kinase function. A) Crystal structure of the auto-inhibited ABL core (PDB: 2FO0) [11]. Key
features include the N-cap, SH3 and SH2 domains, the SH2-kinase linker, and the kinase domain. The disordered portion of the N-cap is indicated by the
dotted line. The N-terminal portion of the N-cap is myristoylated and engages a deep pocket in the kinase domain C-lobe. B) Cartoon depiction of the
intramolecular interactions regulating assembly of the downregulated ABL core. Note that the linker forms a polyproline helix that binds in cis to the SH3
domain. C) Fluorescence polarization (FP) assay. The FP assay combines a recombinant ABL Ncap-SH3-SH2-linker (N32L) protein and a SH3-binding
peptide probe labeled with a fluorescent moiety (F). The probe peptide binds the SH3 domain in the ABL N32L protein, resulting in an FP signal. Small
molecules (S) may bind to the SH3 domain and block probe peptide binding directly; such molecules would be expected to disrupt SH3:linker interaction
(case 1). Alternatively, small molecules may stabilize SH3:linker interaction, making the SH3 domain inaccessible to the probe peptide (case 2). In either
case, small molecule binding is predicted to result in a loss of the FP signal.
doi:10.1371/journal.pone.0133590.g001
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In this study, we report the development and validation of a high-throughput screening
assay for the identification of small molecules that interact directly with the non-catalytic
region of the ABL core. Our assay is based on the interaction of a fluorescent probe peptide
with the SH3 domain in the context of a recombinant protein encompassing the regulatory
region of the ABL core (Ncap-SH3-SH2-linker; referred to hereafter as the ABL ‘N32L’ pro-
tein). Interaction of the probe peptide with the ABL N32L protein results in fluorescence polar-
ization (FP), providing a convenient assay for SH3 occupancy in a format compatible with
high-throughput chemical library screening. In theory, small molecules that bind to SH3 and
disrupt probe binding may also disrupt SH3:linker interaction in the context of ABL, resulting
in kinase activation. On the other hand, compounds that enhance internal SH3 binding to the
natural linker may represent allosteric inhibitors. Using this FP approach, we screened a small
library of FDA-approved drugs and identified a compound that specifically inhibited the FP
signal from the complex of the ABL N32L protein with the probe peptide, suggesting that it
may interfere with SH3:linker interaction. This compound, a substituted pyrimido-pyrimidine
known as dipyridamole, was confirmed to bind directly to the ABL N32L protein using both
differential scanning fluorimetry and surface plasmon resonance. Dipyridamole was found to
enhance the activity of a recombinant downregulated ABL core protein, but had no effect on
an ABL core with engineered high-affinity SH3:linker interaction or on the SRC-family kinase,
HCK. These observations suggest that dipyridamole binds selectively to the ABL SH3 domain,
resulting in linker displacement and kinase activation. This binding model is supported by
molecular dynamics (MD) simulations and molecular docking. Our findings provide an
important proof-of-concept that small molecules acting on the ABL SH3:linker interface can
allosterically modulate ABL kinase activity, and provide a simple yet powerful assay method
for their discovery.
Materials and Methods
Expression and purification of recombinant kinase proteins
The coding sequence for the ABL Ncap-SH3-SH2-linker region (N32L; corresponding to resi-
dues 2–255 with an internal deletion of residues 15–56; numbering based on the crystal struc-
ture of the human ABL core; PDB: 2FO0 [11]) was amplified by PCR and subcloned into the
bacterial expression vector, pET21a (EMDMillipore). A similar construct was prepared using
the sequence of ABL with a high-affinity linker (‘HAL9’) substitution as described previously
[8]. One glycine and six histidine residues (GHHHHHH) were introduced at the N-terminus
of the coding sequence of these proteins during sub-cloning. An inactivating mutation of the
SH3 domain (W118A) was introduced by site-directed mutagenesis using the QuikChange II
method (Stratagene) and the pET21a-ABL N32LWT plasmid as a template. The ABL N32L
proteins were expressed in E.coli strain Rosetta2(DE3)pLysS (EMDMillipore) and purified
using immobilized metal affinity chromatography. The purified proteins were then dialyzed
against 20 mM Tris-HCl (pH 8.3) containing 200 mMNaCl and 1 mMDTT.
The wild type and high-affinity linker (‘HAL9’) ABL core proteins (residues 1–531 with an
internal deletion of residues 15–56) were expressed in Sf9 insect cells as previously described
[8]. The ABL core proteins were purified using a combination of ion-exchange and affinity
chromatography and dialyzed against 20 mM Tris-HCl (pH 8.3) containing 100 mMNaCl and
3 mM DTT. The molecular weight and purity of all recombinant ABL proteins were confirmed
by SDS-PAGE and mass spectrometry.
The SRC-family kinase HCK-YEEI was expressed in Sf9 insect cells and purified as previ-
ously described [19].
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Peptide synthesis
ABL SH3 domain-binding peptides p41, p40, p8, and 3BP-1 [20,21] were synthesized by the
University of Pittsburgh Genomics and Proteomics Core Laboratories. For the FP assay, the
peptides were labeled with 6-carboxyfluorescein at their N-termini. Molecular weight and purity
of all peptides were verified by mass spectrometry. Stock solutions (10 mM) were prepared in a
1:1 mixture of DMSO and FP assay buffer (20 mM Tris-HCl, pH 8.3) for labeled peptides and
neat FP assay buffer for unlabeled peptides. Peptide stock solutions were stored at -20°C.
Fluorescence polarization assay
Fluorescence Polarization (FP) experiments were performed in quadruplicate in low volume
black 384 well plates with a non-binding surface (Corning; catalog # 3676). Peptides and proteins
were added to each well in FP assay buffer (20 mMTris-HCl, pH 8.3) for a final assay volume of
20 μL and mixed by shaking for 5 min at room temperature. The FP signal in millipolarization
(mP) units was measured at an excitation wavelength of 485 nM and emission wavelength of
515 nM in a SpectraMax M5microplate reader (Molecular Devices) using the Softmax Pro soft-
ware (version 5.4.1). Each plate was read three times and the values were averaged prior to analy-
sis. Raw fluorescence intensity was also read at the same wavelengths for each assay.
Chemical library screening
A collection of 1200 FDA-approved small molecules (Prestwick Chemical, Inc.) was used in a
pilot screen with the FP assay. Each library compound was screened at 10 μM and a final
DMSO concentration of 1%. Compounds were added to 384-well assay plates first, followed by
a pre-mixed complex of the ABL N32L protein (25 μg) and the p41 probe peptide (50 nM).
Each plate also contained twenty-eight wells of the wild type N32L protein plus p41 probe and
DMSO as positive controls as well as twenty-eight wells of mutant ABL N32L-W118A protein
plus p41 probe peptide and DMSO as negative controls. Each plate was mixed on the shaker
for 5 min, read three consecutive times, and the average FP signal for each well was calculated.
To identify potential hit compounds, three measures were used: (i) average FP signal; (ii) con-
trol normalized percent inhibition, in which the FP signal with each compound was normal-
ized to the mean FP signal of the positive and negative plate controls according to the formula:
[(sample FP–mean FPWT) / (mean FPW118A –mean FPWT) x 100] [22,23]; (iii) Z score, a statis-
tical measure of variation of the mean sample FP signal that is independent of plate controls,
calculated according to the formula: [(sample FP–mean FPsamples) / standard deviationsamples]
[22,23]. The compounds were then ranked in order of increasing FP signal, decreasing control
normalized percent inhibition, and increasing Z score. Potential hit compounds were then
retested in quadruplicate using the FP assay under screening assay conditions.
Differential Scanning Fluorimetry
Hit compounds (100 μM) were pre-incubated with the ABL N32L WT protein (1 μM) for 30
minutes in bicine assay buffer (10 mM bicine, 150 mMNaCl, pH 8.0). SYPRO Orange (Sigma)
was added at 5X final concentration and fluorimetry profiles were acquired with a StepOnePlus
real-time quantitative PCR instrument (Applied Biosystems) and software (version 2.3). Assays
were performed in duplicate in sealed MicroAmp Fast 96-well qPCR plates (Applied Biosys-
tems), and control reactions without proteins were included to correct for background fluores-
cence. Assays were equilibrated at 25°C for 2 minutes, followed by an increase in temperature
at the rate of 1% (1.6°C/min) to 99°C, with continuous data collection. Mean fluorescence
intensities, after subtracting background fluorescence, were plotted against temperature. Non-
HTS Assays for Chemical Probes of ABL Kinase
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linear regression analysis using the Boltzmann sigmoid function in GraphPad Prism 6 was
used to determine the Tm values, the midpoint of the melt curve between the minimum and
maximum fluorescence intensities.
Surface Plasmon Resonance (SPR)
SPR analysis was performed on a BIAcore T100 instrument (GE Healthcare) using four-chan-
nel CM5 biosensor chips at 25°C. Recombinant purified ABL proteins were covalently attached
to the CM5 chip via standard amine coupling chemistry [24,25]. Compound 142 (dipyrida-
mole; Prestwick Chemical) was prepared in 20 mM Tris-HCl, pH 8.3, 150 mMNaCl and 0.1%
DMSO and flowed past the immobilized ABL protein channel and a reference channel on the
biosensor at a flow rate of 50 μL/min for 3 min over a range of concentrations. The initial bind-
ing reaction was followed by dissociation for 5 min, and the chip surface was regenerated using
20 mM Tris-HCl, pH 8.3, 150 mMNaCl, 0.1% DMSO, 0.05% Tween 20 and 1 mMDTT at a
flow rate of 50 μL/min for 10 min. Sensorgrams were recorded in triplicate, corrected for buffer
effects, and fitted with the 1:1 Langmuir binding model using the BIAevaluation software suite
version 2.0.4 (GE Healthcare).
Protein kinase assays
The ADP Quest assay (DiscoverRx) [26], which fluorimetrically measures kinase activity as the
production of ADP, was used to determine ABL kinase reaction velocities. Assays were per-
formed in quadruplicate in black 384 well plates (Corning #3571) in reaction volumes of
10 μL/well. Recombinant kinase protein concentrations were fixed at 40 ng/well for the wild
type ABL core, 9 ng/well for the high affinity linker ABL core, and 250 ng/well for the SRC fam-
ily kinase HCK. The Tyr2 substrate peptide for ABL (EAIYAAPFAKKK) as well as the SFK
substrate peptide (YIYGSFK) were dissolved in the ADP Quest assay buffer (15 mMHEPES,
pH 7.4, 20 mMNaCl, 1 mM EGTA, 0.02% Tween-20, 10 mMMgCl2, 0.1 mg/ml bovine γ-glob-
ulins), while ATP stocks were prepared in 10 mM Tris-HCl (pH 7.0). Each kinase reaction was
initiated by the addition of ATP and read at 5 min intervals for 3 h in a SpectraMax M5 Micro-
plate reader (Molecular Devices). To determine the substrate Km for ABL kinases, the ATP
concentration was fixed at 50 μM and the substrate peptide was serially diluted from 0.2–
200 μM. For ABL kinase ATP Km determination, the substrate concentration was fixed at the
respective substrate Km for each of the kinases, and the ATP concentration was titrated over
the range of 0.2–200 μM. The resulting progress curves were analyzed according to the method
of Moroco et al. [19]. Briefly, raw fluorescence data were corrected for non-enzymatic ADP
production (no kinase or substrate control) and kinase auto-phosphorylation (rate observed in
the absence of substrate), and converted to pmol ADP produced using an ADP standard curve
generated under the same reaction conditions. The resulting values were normalized to the
amount of kinase present in each reaction, and plotted against time. The linear portion of each
progress curve was fit by regression analysis to determine the reaction velocity. Substrate and
ATP Km values were determined by non-linear regression analysis using the Michaelis-Menten
equation (GraphPad Prism 6).
Half-maximal effective concentrations (EC50) and activation constants (Kact) were deter-
mined for the ABL kinase core by both dipyridamole and the known ABL activator, DPH (5-
(1,3-diaryl-1H-pyrazol-4-yl)hydantoin; Sigma-Aldrich) [27]. The kinase was pre-incubated with
each compound (10 nM to 100 μM) for 30 min at room temperature, followed by kinase assay
with the substrate and ATP concentrations fixed at their respective Km values. The rate of each
reaction was plotted against compound concentration, and analyzed by non-linear regression
analysis (GraphPad Prism 6) to determine the EC50 value. To determine the activation constant
HTS Assays for Chemical Probes of ABL Kinase
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Kact, the basal rate of kinase activity was subtracted from the rates of reaction in the presence of
each compound concentration, and plotted as a function of compound concentration. The
resulting curves obeyed saturation kinetics and were best-fit by the following equation [19]:
Va ¼ Vact½L=ðKact þ ½LÞ
where Va is the reaction velocity in the presence of each activator concentration, Vact is the maxi-
mal reaction velocity, L is the activator concentration, and Kact is the activator concentration that
yields half-maximal reaction velocity.
Molecular dynamics
To understand the dynamics of the recombinant N32L protein, for which there is no X-ray
crystal structure, we ran unconstrained molecular dynamics (MD) simulations of residues 65–
254 of the assembled, downregulated ABL core structure (PDB 2FO0). We disrupted the inter-
action between linker Pro249 and the SH3 domain by rotating the backbone bonds of linker
Gly246. This glycine residue was chosen as a pivot point as it is more flexible and is located
between Pro249 and the next strongly interacting residue (Val244) based on the predicted
interaction energy with the SH3 domain [28]. We also ran MD simulations of the (unmodified)
isolated SH3 domain (residues 80–145) using the same parameters described below.
MD simulations were conducted with the pmemd.cuda [29] module of AMBER14 [30],
using the force fields AMBER ff14SB and gaff (general amber force fields) [31]. An octahedral
TIP3P water box was constructed with 12 Å from the edge of the box to the solute and the total
system charge was neutralized by adding chloride ions. The non-bonded cutoff was specified at
10 Å. In the first energy minimization run, the solute was held fixed and the solvent was relaxed
through 500 cycles of steepest descent followed by 500 cycles of conjugate gradient minimiza-
tion. Subsequently, the system was minimized again with no constraints through 2,000 cycles
of steepest descent followed by 3,000 cycles of conjugate gradient minimization. Following the
energy minimization, a 50,000 step MD simulation was used to raise the system temperature to
300 K while holding the solute fixed with weak (10.0 kcal/mol) restraints on the solute atoms.
The bonds involving hydrogens were held at a fixed length and an integration step of 2 fs was
used. This simulation was followed by a second equilibration simulation at constant pressure
for 50,000 steps. The final MD simulation of this equilibrated structure was run with no con-
straints for 100 ns.
Computational docking
The binding mode of hit compound 142 (dipyrimadole) was modeled to snapshots of the N32L
and SH3 simulations by molecular docking using the program smina [32] with default docking
parameters. The box was defined by the coordinates of linker residues 247–251 plus an outer
shell of 8 Å after alignment to the SH3 domain of the crystal structure (PDB 2FO0).
Transient expression of ABL core proteins in 293T cells
ABL core proteins were expressed in human 293T cells and analyzed for kinase activity as
described elsewhere [8]. Briefly, cells were grown overnight in 60 mm plates, transfected with
an expression vector for the wild type ABL core, and treated with compounds 2 h post- trans-
fection. Cells were lysed by sonication 24 h later, and cell lysates clarified by centrifugation.
ABL was immunoprecipitated via the C-terminal His-tag, resolved by SDS-PAGE, and trans-
ferred to nitrocellulose membranes for immunoblot analysis with antibodies to the ABL pro-
tein and the three autophosphorylation sites: pTyr412 (activation loop), pTyr245 (SH2-kinase
linker), and pTyr89 (SH3 domain).
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Results and Discussion
ABL fluorescence polarization (FP) assay design
In this study, we developed a screening assay for small molecule allosteric modulators of ABL
kinase function. Our goal was to enable discovery of chemical scaffolds that interact with the
regulatory region of the ABL kinase core, as opposed to the kinase domain, thereby providing a
path to enhanced selectivity and allosteric control of kinase function. In addition, we wanted a
flexible assay with the potential to identify both inhibitors and activators of ABL function. To
accomplish these goals, we developed a fluorescence polarization (FP) assay based on the N-
terminal region of ABL consisting of the Ncap, SH3 and SH2 domains, and the SH2-kinase
linker (ABL N32L protein). Binding of a fluorescently labeled probe peptide to the SH3 domain
(displacing the linker) should result in an increased FP signal due to the slowed rotation of the
N32L target protein-peptide complex (Fig 1C). A small molecule that binds to the ABL N32L
protein and enhances SH3 interaction with the linker in cis is predicted to prevent probe pep-
tide binding, resulting in a decrease in the FP signal. Molecules in this class are predicted to act
as allosteric inhibitors of ABL kinase activity, because they may enhance the natural negative
regulatory interaction between the SH3 domain and the linker. Alternatively, compounds that
interact with the SH3 domain and block probe peptide binding are also predicted to cause a
decrease in the FP signal. By displacing SH3:linker interaction in the context of downregulated
ABL, compounds of this type may act as allosteric activators of kinase activity. This assay
design therefore has the potential to identify both types of ABL-binding compounds in a single
chemical library screen. Their impact on ABL function can be easily distinguished in secondary
assays for direct binding to the ABL domains, as well as functional assays.
Recombinant ABL regulatory proteins for FP assay development
The target protein for the ABL FP assay consists of the first 255 residues of ABL (isoform 1b),
and encompasses the Ncap, the SH3 and SH2 domains, as well as the SH2-kinase linker as
described above. This ABL N32L protein was expressed in bacteria in soluble form, purified to
homogeneity, and its purity and identity were confirmed by SDS-polyacrylamide gel electro-
phoresis and mass spectrometry, respectively (Fig 2). Previous studies have established that
regulatory SH3:linker interaction is maintained in this construct, despite the absence of the
kinase domain [8,33]. In addition to the wild type protein, two mutant forms of N32L were
produced for use as controls. The first of these has an alanine substitution for a conserved tryp-
tophan on the SH3 domain binding surface (W118A mutant; see Fig 3 for SH3 domain struc-
ture), which renders it unable to bind to the probe peptide and thus serves as a negative
control. In the second mutant, five linker residues were replaced with prolines to enhance
interaction with the SH3 domain [8]. This high-affinity linker (HAL) substitution suppresses
the activating effects of kinase domain mutations and influences the conformation of the kinase
domain, enhancing both imatinib and allosteric inhibitor action (see Introduction). The HAL
protein therefore represents a second negative control for probe peptide binding to the SH3
domain. Both the W118A and HAL forms of the ABL N32L protein were also expressed and
purified from bacteria, and yielded soluble purified proteins of the expected mass (Fig 2).
Structural basis for high affinity probe peptide binding to the ABL SH3
domain
A suitable probe for the ABL N32L FP assay required a short, proline-rich peptide with
sequence specificity for the ABL SH3 domain. In addition, the probe peptide needed to bind to
the SH3 domain with sufficient affinity to compete for cis-interaction of the SH3 domain with
HTS Assays for Chemical Probes of ABL Kinase
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the natural linker (Fig 1). A survey of the literature identified four ABL SH3-binding peptides
with the potential to serve as probes [20,21]. These peptides, designated p41, p40, p8, and 3BP-
1, have KD values for the ABL SH3 domain in the 0.4 to 34 μM range. The ABL SH3-binding
peptide sequences are presented in Fig 3A, and are aligned with those of the wild type and
high-affinity SH2-kinase linkers of ABL.
To explore the potential of known ABL SH3 peptide ligands to compete for natural SH3:
linker interaction, we first compared the structure of the ABL SH3:linker interface from the
downregulated ABL core (PDB: 2FO0) [11] with the crystal structure of the p41 peptide in
complex with the ABL SH3 domain (PDB: 1BBZ) [21]. The C-terminal half of the p41 peptide
is comprised exclusively of proline, which facilitates both PPII helix formation as well as tight
interaction with the hydrophobic SH3 binding surface (Fig 3B). In contrast, this region of the
SH2-kinase linker is comprised of the less favorable SH3-binding sequence, KPTVY (Fig 3C).
Specifically, p41 proline residues 9 and 10 fill the hydrophobic groove formed by the aromatic
side chains of SH3 tyrosines 89 and 134; the linker is substituted with lysine in this position
(Lys241). The main chain carbonyl of p41 Pro8 forms a stabilizing hydrogen bond with
Tyr134. This position is substituted with threonine (Thr243) in the linker, which swings away
from the SH3 surface. The N-terminal sequence of the p41 peptide forms a network of polar
contacts involving SH3 residues Ser94, Asp96, and Trp118. None of these contacts are present
in the SH3:linker interface, and the side chain of SH3 Asp96 is rotated away from the linker.
Fig 2. Recombinant ABL Ncap-SH3-SH2-linker (N32L) proteins.Wild type ABL N32L protein and the corresponding high-affinity linker (HAL) andW118A
mutants were expressed in E. coli using the pET system [40] and purified by immobilized metal affinity chromatography. Protein purity and mass were verified
by SDS polyacrylamide gel electrophoresis (A) and mass spectrometry (B).
doi:10.1371/journal.pone.0133590.g002
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Taken together, these structural features strongly suggested that p41, or one of the closely
related peptides (p40, p8, and 3BP-1), may interact with the ABL N32L target protein with suf-
ficient affinity to displace the wild type linker and provide a stable FP signal.
Selection of a probe peptide for the ABL N32L FP assay
To evaluate the suitability of the four ABL SH3 peptide ligands (p41, p40, p8, 3BP-1; Fig 3A) as
FP probes, each peptide was synthesized and labeled with 6-carboxyfluorescein on its N-termi-
nus. We first examined the baseline FP signal as well as the fluorescence intensity exhibited by
each labeled peptide over a broad concentration range (1–1,000 nM) in the absence of the ABL
Fig 3. Peptide and linker interactions with the ABL SH3 domain. A) Sequences of the ABL SH3 binding peptides, p41, p40, p8, and 3BP-1, and their
published binding affinities for the ABL SH3 domain [20,21]. Sequences of the wild type (WT) and high-affinity (HAL) SH2-kinase linker sequences are also
shown at the bottom. The peptide sequences are presented in the C- to N-terminal orientation to align with those of the linkers. B) Crystal structure of the p41
peptide (cyan) bound to the ABL SH3 domain (PDB: 1BBZ) [21]. The SH3 surface is shown as a space filling model (red) and side chains of residues that
interact with the p41 peptide are shown as sticks. C) Crystal structure of the SH2-kinase linker (orange) bound to the ABL SH3 domain (red) from the ABL
core (PDB: 2FO0) [11]. Side chains of SH3 domain residues that interact with the p41 peptide as per panel B are shown as sticks. Note the lack of
hydrophobic interactions and hydrogen bonds between the SH3 domain and the linker in comparison to the p41 peptide.
doi:10.1371/journal.pone.0133590.g003
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N32L target protein. As shown in Fig 4A, probe peptide concentrations greater than 50 nM
exhibited stable baseline FP readings with minimal well-to-well variation.
To test for ABL N32L protein interaction with each peptide in the FP assay, we held each
probe peptide concentration at 50 nM and added the wild type N32L protein over a range of
concentrations. As shown in Fig 4B, both the p40 and p41 probe peptides produced a strong,
saturable FP signal as a function of the N32L protein concentration. The p8 peptide also pro-
duced an FP response, albeit somewhat lower than that observed with p40 and p41, while the
3BP-1 peptide was inactive. These FP results correspond to the rank order of binding affinities
previously reported for these peptides with the isolated SH3 domain [20,21]. Since the struc-
ture of the ABL SH3 domain in complex with p41 is known (Fig 3B), we chose the p41 peptide
for FP assay optimization.
ABL N32L FP assay development and optimization
We next investigated whether the FP signal obtained with the p41 probe peptide was due to
interaction with SH3 domain of the recombinant ABL N32L target protein. For these experi-
ments, we compared the FP signal produced from the wild type ABL N32L protein with the
SH3 domain mutant (W118A) as well as the high-affinity linker (HAL) protein. As shown in
Fig 5A, the wild type ABL N32L protein produced a concentration-dependent increase in the
FP signal as observed previously. In contrast, the N32LW118A mutant failed to produce an FP
signal with the p41 peptide over the same concentration range, indicating that the peptide
requires this conserved SH3 domain tryptophan residue for binding as predicted from the crys-
tal structure (see Fig 3). On the other hand, the ABL N32L HAL protein showed a greatly
reduced FP signal in comparison to the wild type protein with the p41 probe. This result is con-
sistent with enhanced cis-interaction of the linker with SH3 domain in this protein as a result
of the higher linker proline content (see Fig 3A for HAL sequence). Results with these control
proteins demonstrate that the p41 probe peptide interacts with the ABL N32L target protein
through its SH3 domain. FP experiments with the recombinant purified ABL SH3 domain
alone also produced a very similar FP response, supporting this conclusion (data not shown).
Findings with these ABL N32L mutants support the idea that small molecules that disrupt or
stabilize intramolecular interaction between the SH3 domain and linker will also reduce probe
peptide binding and loss of the FP signal.
We next tested the stability of the FP signal as a function of time (Fig 5B). For this experi-
ment, the p41 probe peptide (50 nM) and ABL N32L protein (12.8 μg/well) concentrations
were held constant. Under these conditions, no significant variation in the FP signal was
observed up to 10 hours. We also found that DMSO, the carrier solvent for the screening
library compounds, did not influence the FP signal or the negative controls even at the highest
concentration tested (1%; Fig 5C).
In a final validation experiment, we tested the effect of unlabeled p41 peptide on the FP sig-
nal (Fig 5D). For this study, we fixed the p41 probe peptide concentration at 50 nM and the
wild type ABL N32L protein concentration at 20 μg/well. Unlabeled p41 peptide was added to
the assay over the concentration range of 2.5 to 100 μM. The FP signal decreased as a function
of unlabeled p41 peptide concentration, demonstrating competition for the labeled probe pep-
tide binding to the N32L protein. As a negative control, the peptide competition experiment
was repeated with a non-specific peptide of similar length. This peptide had no effect on the FP
signal, even at a concentration of 100 μM, demonstrating the specificity of p41 peptide recogni-
tion by the SH3 domain in the N32L target protein.
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Identification of inhibitors of p41 interaction with ABL N32L
To test the performance of the ABL N32L FP assay under screening conditions, we performed
a pilot screen of 1200 FDA-approved compounds. The wild type ABL N32L protein (25 μg)
was added to each well together with the p41 probe peptide (50 nM). The compounds were
then added to a final concentration of 10 μM in 1% DMSO. Each plate contained twenty-eight
wells with the wild type N32L target protein plus DMSO as positive controls, and twenty-eight
Fig 4. Identification of p41 as optimal probe peptide for the ABL N32L FP assay. A) To characterize the
baseline FP signal, the 6-carboxy-fluorescein labeled probe peptides p41 (red), p40 (green), p8 (blue), and
3BP-1 (black) were serially diluted in the concentration range of 1–1000 nM. The FP signals (solid lines, left Y
axis) and corresponding fluorescence intensities (dashed lines, right Y axis) were measured and plotted as a
function of peptide concentration. Average values are shown ± SE from four measurements per condition. B)
To test for probe peptide interaction with ABL N32L by FP, each peptide (50 nM) was incubated with the ABL
N32L protein over the range of 0.08–25 μg/well. The resulting FP signals were corrected for baseline FP
signal recorded in the absence of the N32L protein and plotted against the N32L protein concentration.
Average FP values are shown ± SE from four measurements per condition; error bars are smaller than the
diameter of some data points.
doi:10.1371/journal.pone.0133590.g004
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wells with the non-binding W118A mutant protein plus DMSO as negative controls. The over-
all Z factor for the pilot screen was 0.57, indicative of a reliable screening assay [34]. The aver-
age FP signals observed with the controls as well as the readings observed with each of the test
compounds are presented in Fig 6A.
The FP signals for each compound were ranked by three different methods: increasing raw
FP signal, decreasing normalized percent inhibition, and increasing Z score (see Materials and
Methods). We then compared the top 1% of compounds present in each of these three rank-
ings. Five compounds were present in at least two of these rankings, and were selected for fol-
low-up assays (compound numbers 3, 42, 142, 787, and 1415; Fig 6A). Each of the raw hit
compounds was then retested in multiple wells under screening assay conditions (Fig 6B). Four
Fig 5. ABL N32L FP assay development and optimization. A) The p41 FP probe binds the ABL N32L protein through the SH3 domain. The p41 probe
peptide (50 nM) was combined with wild type, HAL, andW118A ABL N32L proteins over the range of concentrations shown. The resulting FP signals were
measured and plotted as a function of N32L protein concentration. B) FP assay stability. The p41 probe peptide (50 nM) was combined with the three ABL
N32L proteins (12.8 μg/well) and FP signals were recorded over the time course shown. C) DMSO tolerance. FP assays consisting of the p41 probe peptide
(50 nM) and each ABL N32L protein (25 μg/well) were incubated with the DMSO concentrations shown, and FP signals were recorded 1 h later. D)Unlabeled
peptide competition. For the competition assay, the p41 probe peptide (50 nM) was mixed with unlabeled p41 peptide or a negative control peptide of
unrelated sequence (QKEGERALPSIP) and similar length (Con) over the range of concentrations shown. The ABL N32L protein (20 μg/well) was then
added, and FP signals were recorded. FP signals were corrected for the background p41 peptide FP signal and plotted as a function of the unlabeled peptide
concentration. In all experiments (A through D), average FP values are shown ± SE from four measurements per condition.
doi:10.1371/journal.pone.0133590.g005
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Fig 6. Pilot screen identifies inhibitors of p41 interaction with the ABL N32L protein. A) A library of 1200 FDA-approved compounds was screened
using the ABL N32L protein (25 μg/well) and the p41 probe peptide (50 nM) in the FP assay. The solid lines correspond to the mean FP signals for the wild
type (WT) and SH3mutant (W118A) control N32L proteins across all assay plates, with the dotted lines indicating three standard deviations from the means
(± 3σ). Compounds were screened at 10 μM and each FP signal is represented as an individual circle. Five putative hit compounds were identified (green
circles). B) The five potential hit compounds were re-tested in quadruplicate at 10 μM vs. the DMSO control under FP screening assay conditions, and the
mean FP values are shown ± SE. Four of these compounds significantly inhibited the FP signal relative to the DMSO control as indicated by the asterisk
(p < 0.05; 2-tailed t-test). The dotted line shows the FP value three standard deviations below the DMSO control FP signal (-3σ).
doi:10.1371/journal.pone.0133590.g006
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out of the five compounds produced a significant inhibition of the FP signal relative to the
DMSO controls (compounds 42, 142, 787, and 1415). We then performed control FP experi-
ments with each of these compounds under the same conditions but in the absence of the
N32L target protein. This counter-screen showed that compound 787 also inhibited the base-
line FP signal produced by the p41 probe peptide, indicating non-specific quenching of the FP
signal (data not shown). None of the other compounds affected baseline p41 probe peptide
fluorescence, and were therefore moved forward into secondary assays.
Compounds identified in the ABL N32L FP screen interact directly with
the ABL N32L protein in orthogonal assays
As an independent measure of hit compound interaction with the ABL N32L target protein, we
performed differential scanning fluorimetry assays [35]. For these experiments, the ABL N32L
protein was heated with a molar excess of each compound in the presence of the reporter dye,
SYPRO orange. As the temperature rises and the N32L protein unfolds, the reporter dye
accesses the hydrophobic interior of the protein, resulting in an increase in dye fluorescence.
The resulting protein ‘melt curve’ is then fit by regression analysis to obtain a Tm value, the
temperature at which half-maximal thermal denaturation is observed. Small molecule binding
to a target protein can either increase or decrease the Tm value, depending upon the effect of
the compound on protein stability. Differential scanning fluorimetry was performed with the
wild type N32L protein in the presence of each of the hit compounds from the FP assay, and
the change in Tm value (ΔTm) was determined compared to DMSO as the reference control. As
shown in Fig 7A, all four compounds produced a significant decrease in the Tm value. Com-
pound 142 had the largest impact on N32L thermal stability, producing a decrease of more
than 2°C in the Tm, consistent with its effect in the FP assay (Fig 6B).
To confirm direct interaction of compound 142 with the ABL N32L protein and explore the
binding kinetics, we next performed surface plasmon resonance assays. For these experiments,
the ABL N32L protein was immobilized on the biosensor surface while compound 142 was flo-
wed past the immobilized protein over a range of concentrations. As shown in Fig 7B, concen-
tration-dependent interaction of compound 142 with ABL N32L was readily detected by this
approach, yielding an association rate constant of 3.87 ± 0.59 x 103 M-1s-1 and a dissociation
rate constant of 2.70 ± 0.72 x 10−2 s-1. The equilibrium dissociation constant (KD) for this inter-
action, calculated as the ratio of kd/ka, is 6.90 ± 0.78 x 10
−6 M.
Compounds that inhibit the FP signal in the ABL N32L assay may either interfere directly
with probe peptide binding to the SH3 domain or allosterically tighten the cis-interaction of
the SH3 with the linker, indirectly reducing probe peptide interaction. To distinguish between
these two possibilities with compound 142, we performed FP assays with the N32L protein as
well as the isolated ABL SH3 domain. As shown in Fig 7C, Compound 142 resulted in a con-
centration-dependent decrease in the FP signal with both the ABL N32L and SH3 proteins,
suggesting that this compound binds directly to the ABL SH3 domain.
Allosteric activation of ABL kinase by compound 142
Compound 142 reproducibly scored as a hit in the ABL N32L FP assay and demonstrated
direct interaction with ABL N32L protein by both differential scanning fluorimetry and SPR.
This compound, a symmetrically substituted pyrimido-pyrimidine known as dipyridamole
(Fig 7D), is a selective inhibitor of phosphodiesterase V and also an adenosine transport inhibi-
tor used clinically for its antithrombotic activity [36]. However its potential impact on protein
kinase function has not been reported. Because compound 142 interacts with the regulatory
region of ABL, we investigated its effects on ABL kinase activity using two purified
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recombinant forms of ABL in a kinetic kinase assay. These included the wild type ABL core
region, consisting of the Ncap, the SH3 and SH2 domains, the SH2-kinase linker, and the
kinase domain. This ABL protein was produced in Sf9 insect cells, which results in myristoyla-
tion of the N-cap and interaction with the C-lobe of the kinase domain, thereby assembling the
downregulated state (Fig 1A). In addition to the wild type core, we also tested a high-affinity
linker (HAL) mutant version of the ABL protein, which has a modified proline-rich linker that
packs more tightly against the SH3 domain [8].
Fig 7. Hit compound 142 interacts directly with the ABL N32L protein. A) Differential scanning fluorimetry assays were performed on the ABL N32L
protein in the presence of the four confirmed hit compounds as described under Materials and Methods. The average change in the mid-point of the thermal
melt profile (ΔTm) relative to the Tm obtained with the N32L protein in the presence of the DMSO carrier solvent is plotted on the Y-axis ± SE (n = 2). B)
Surface plasmon resonance was performed with the ABL N32L protein immobilized on the biosensor chip and compound 142 as analyte. Responses were
recorded for the four compound concentrations shown, and the flow path was switched back to buffer after 180 s to induce dissociation (arrow). The resulting
sensorgrams (black lines) were fit by a 1:1 Langmuir binding model (red lines) to generate kinetic constants. C) Compound 142 inhibits p41 peptide binding to
the ABL N32L and SH3 proteins in the FP assay. Compound 142 was added to N32L and SH3 FP assays over the range of concentrations shown, and the
resulting FP signals are presented as the mean ± SE. Significant inhibition for both N32L and SH3 was observed at 3 and 10 μM (*p < 0.05 by 2-tailed t-test).
D) Chemical structure of compound 142 (dipyridamole).
doi:10.1371/journal.pone.0133590.g007
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Baseline kinase activities and kinetic parameters of each recombinant ABL kinase core pro-
tein were determined first using a fluorimetric assay that measures the kinase reaction rate as
the generation of ADP [26]. For wild type ABL, we obtained Km values of 9.78 ± 0.14 μM and
144.65 ± 1.64 μM for ATP and peptide substrate, respectively. The ABL HAL core yielded a
similar Km value for substrate (150.25 ± 5.35 μM), with a higher value for ATP
(21.24 ± 1.6 μM). In subsequent experiments, the ATP and peptide substrate concentrations
were set to their respective Km values, and input kinase concentrations were adjusted to yield
the same basal reaction rates (7 pmol ADP produced per minute).
We first examined the effect of compound 142 on the activity of the wild type ABL kinase
core protein. As shown in Fig 8, compound 142 stimulated wild type ABL kinase activity by
about 40% at a concentration of 10 μM relative to the DMSO control in this assay. As a positive
control, we also assayed ABL core activity in the presence of the same concentration of a previ-
ously described ABL activator, DPH, and observed a similar degree of activation. DPH, unlike
compound 142, stimulates ABL through the kinase domain via the myristic acid binding
pocket in the C-lobe [27].
The mechanism of ABL activation by compound 142 may involve binding to the SH3
domain and subsequent displacement of its regulatory interaction with the SH2-kinase linker.
Indeed, mutations that disrupt SH3:linker interaction also have a stimulatory effect on ABL
kinase activity (see Introduction). To test this idea, we next examined the effect of this com-
pound on the ABL core mutant with enhanced SH3:linker interaction. Unlike wild type ABL,
compound 142 did not affect the kinase activity of the ABL core with the HAL substitution
(Fig 8), consistent with the idea that enhanced SH3:linker interaction prevents compound 142
access to the ABL SH3 domain. Interestingly, DPH did not activate the ABL HAL core protein
either, consistent with previous results showing that enhanced SH3:linker interaction over-
comes ABL core activation by mutations in the myristic-acid binding pocket [8].
To further characterize ABL activation by compound 142, we repeated kinetic kinase assays
with the wild type ABL core over a range of compound concentrations. As shown in Fig 9,
compound 142 activates the ABL core in a concentration-dependent manner, with an EC50
value of 0.63 ± 0.07 μM. This value compares favorably to that obtained with DPH, the myristic
acid binding pocket agonist (EC50 = 1.11 ± 0.5 μM). We also calculated the activation constant
(Kact) for each compound from these data, which is defined as the concentration at which the
reaction rate reaches half-maximum velocity (Vact). For compound 142, the Kact was calculated
as 0.4 ± 0.02 μM, while DPH yielded a value of 1.02 ± 0.07 μM. This analysis also showed that
the extent of ABL activation by compound 142 was higher than that observed for DPH, based
on the Vmax.
Molecular dynamics simulations and docking studies predict binding of
compound 142 to the SH3:linker interface in the ABL kinase core
Data presented in the previous sections demonstrate that compound 142 interacts with the reg-
ulatory N32L region of ABL, resulting in a decrease in thermal stability and a concomitant
increase in kinase activity. We used molecular dynamics (MD) simulations to explore the
dynamics of the N32L region used in the assays. To model the effect of the linker being dis-
placed from the SH3 domain, we manually pulled the linker a short distance away from the
SH3 domain prior to the simulation (see Materials and Methods). After approximately 20 ns,
the linker reconnected with the SH3 domain through the interaction of linker Pro249 and SH3
Trp118. To explore possible binding sites for this compound on the N32L region of the ABL
kinase core, we used the computational docking tool smina [32] to dock 142 to snapshots of
the simulation prior to the reconnection of the SH3:linker interface. As shown in Fig 10 (top
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panel), compound 142 fits into a surface pocket defined by the SH3:linker interface in the
N32L protein. This predicted binding site involves an aromatic interaction between the pyri-
mido-pyrimidine moiety of 142 and the indole side chain of SH3 Trp118, as well as polar con-
tacts involving all four hydroxyl groups on the ligand. This aromatic interaction is consistent
with probe peptide displacement as well as the observed decrease in the FP signal produced by
the W118A mutation (Fig 5C). Two of the hydroxyl groups of 142 make potential hydrogen
bonds with the side and main chains of SH3 Asn97 as well as the side chain of Thr98. The
other two hydroxyl groups of 142 form hydrogen bonds with the main chain carbonyls of
Fig 8. Compound 142 activates the ABL kinase core in vitro. Top: The recombinant ABL core protein, consisting of the Ncap, SH3, SH2 and kinase
domains, was assayed in the presence of compound 142 (10 μM), the known ABL activator DPH (10 μM), and imatinib (1 μM) or with DMSO as control (Con)
using a kinetic kinase assay (see Materials and Methods). Data are plotted as pmol ADP produced per ng kinase as a function of time. The cartoon (right)
depicts the domain organization of the wild type ABL core, and indicates the binding site for DPH (myristic acid binding pocket) as well as the predicted
binding site for compound 142 (SH3 domain). Bottom: Kinase assays were performed using an ABL core protein with a high-affinity linker (HAL) in the
presence of the same three compounds; the cartoon indicates the position of the modified linker (HAL). In both cases, the ATP and peptide substrate
concentrations were set to their respective Km values (wild type ABL: 9.78 ± 0.14 μM for ATP and 144.65 ± 1.64 μM for substrate; ABL HAL: 21.24 ± 1.6 μM
for ATP and 150.25 ± 5.35 μM for substrate).
doi:10.1371/journal.pone.0133590.g008
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linker Gly246 and Val247 as well as the side chain of SH3 Asn115. In addition, one of the
piperidine groups of compound 142 makes hydrophobic contacts with SH3 Trp129, while the
other approaches the side chains of linker residues Pro249 and Trp254. Note that in the crystal
structure of the fully assembled, downregulated conformation of the ABL core, linker Pro249
Fig 9. Concentration-dependent activation of the ABL kinase core protein by compound 142. The wild
type ABL kinase core was assayed in the presence of compound 142 and DPH at the indicated
concentrations using a kinetic kinase assay (see Materials and Methods). Reaction velocities are plotted as a
function of compound concentrations. The resulting data were curve-fit to determine the EC50, Kact and Vmax
for each activator as described under Materials and Methods. Each of these parameters was determined in
triplicate, and the mean values ± SE are presented in the table below the graph. The table also provides the
ratio Vmax/Kact as a measure of overall enhancement of catalytic efficiency in the presence of each of these
two ABL agonists.
doi:10.1371/journal.pone.0133590.g009
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Fig 10. Molecular dynamics (MD) andmolecular docking predict binding of compound 142 to the ABL
SH3:linker interface. Top: The lowest energy pose of the ligand (compound 142; carbon atoms rendered in
HTS Assays for Chemical Probes of ABL Kinase
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inserts between SH3 Trp118 and Trp129 (Fig 10, middle panel); displacement of this regulatory
contact by compound 142 binding may contribute to kinase activation.
For comparison, we also ran unconstrained MD simulations of the SH3 domain in the
absence of the linker. Our docked model to a snapshot from this simulation is shown in Fig 10
(bottom panel). The overall position of the ligand in this model is quite similar to that observed
with the N32L snapshot (within 1.5 Å RMSD), and includes the potential stacking interaction
with SH3 Trp118 and hydrogen bonding to SH3 Asn97, Thr98 and Asn115. Polar contacts of
compound 142 with linker Gly246 and Val247 as well as hydrophobic interactions with linker
Trp254 and Pro249 are not possible. However, additional hydrogen bonds are observed with
SH3 Glu117. Loss of these hydrophobic interactions in the SH3-only model helps to explain
the lower binding affinity of compound 142 for the isolated SH3 domain (KD = 3.00 ± 0.40 x
10−5 M) relative to the N32L protein (KD = 6.90 ± 0.78 x 10
−6 M) as determined by SPR (data
not shown and Fig 7B).
Compound 142 does not activate the SRC-family kinase, HCK
Like ABL, SRC-family kinases exhibit a very similar arrangement of SH3, SH2, and kinase
domains in the downregulated conformation, and are also susceptible to activation by muta-
tions and binding partners that disrupt intramolecular SH3:linker interaction [37,38]. To
determine whether compound 142 also activates SRC-family kinases by a similar SH3:linker
displacement mechanism, we performed kinetic kinase assays on the SRC-family member
HCK in the presence and absence of this ABL activator. As shown in Fig 11, addition of com-
pound 142 to recombinant near-full-length HCK had no effect the reaction velocity, suggesting
that it is selective for ABL. Alignment of the SH3 domain and SH2-kinase linker sequences
supports this view (Fig 11, bottom). Five of the seven residues predicted by the docking model
to participate in compound 142 binding to the ABL SH3:linker surface are either substituted
with different amino acids or are missing from the HCK sequence. These observations suggest
that even subtle differences in the SH3 and linker sequences of ABL and SRC-family kinases
can be exploited for the development of selective agonists or antagonists.
Compound 142 cooperates with DPH to activate ABL in cells
In a final series of studies, we evaluated the effect of compound 142 on the activity of the ABL
core in cells. For these studies, we expressed the wild type ABL core in 293T cells, and then
treated the cells over a range of compound 142 concentrations (1–10 μM). We then immuno-
precipitated ABL and analyzed the level of phosphorylation at three important regulatory tyro-
sine sites by immunoblotting with phosphospecific antibodies [8,39]: pY412 (activation loop),
pY245 (SH2-kinase linker), and pY89 (SH3 domain). As shown in Fig 12, treatment with
green) is shown docked to a snapshot of an MD simulation of the ABL N32L structure. SH3 domain residues
predicted to contribute to ligand binding include Asn97, Thr98, Asn115, Trp118, and Trp129 (carbons in red).
The backbone of the linker is shown as an orange ribbon, with Gly246, Val247, Pro249 and Trp254 predicted
to contribute to the binding pocket. One of the piperidine groups of compound 142 makes hydrophobic
contacts with linker Pro249 and Trp254, while the pyrimido-pyrimidine scaffold of compound 142 is π-
stacking with Trp118.Middle panel: Model of the SH3:linker interface in the N32L region based on the crystal
structure of the downregulated ABL core (PDB:2FO0), highlighting the interaction of linker Pro249 with SH3
Trp118 and Trp129. Ligand binding (top panel) is predicted to displace this regulatory interaction, leading to
kinase activation. Lower panel: The lowest energy pose of compound 142 is shown docked to a snapshot of
an MD simulation of the SH3 domain in the absence of the linker. The position of the 142 ligand is similar
(within 1.5 Å RMSD) to that in the SH3 domain of N32L (top), except that the ligand contacts Glu117 rather
than linker residues Gly246 and Val247. Without the linker, the potential hydrophobic stabilization of the 142
piperidine group is also lost.
doi:10.1371/journal.pone.0133590.g010
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Fig 11. Compound 142 fails to activate downregulated HCK in vitro. Top panels: Recombinant,
downregulated wild type ABL core and near full-length HCK proteins were assayed in the presence of
compound 142 (1 μM) or with DMSO alone as control (Con) using a kinetic kinase assay (see Materials and
Methods). Data are plotted as pmol ADP produced per ng kinase as a function of time. Bottom: Amino acid
sequence alignment of the ABL and HCK SH3 domains and SH2-kinase linkers. SH3 and linker residues
predicted to contribute to compound 142 binding are highlighted in red (see Fig 10). The type of interaction is
indicated as side chain (s), main chain (m), or aromatic (a).
doi:10.1371/journal.pone.0133590.g011
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compound 142 alone did not affect phosphorylation of these sites. We then repeated this exper-
iment in the presence of DPH, the myristic acid binding pocket activator described above, at a
concentration of 10 μM. In the absence of compound 142, DPH had a very small effect on ABL
phosphorylation. However, the combination of compound 142 and DPH led to remarkable
enhancement of phosphorylation on all three regulatory tyrosines, providing strong evidence
for an activating effect of compound 142 on ABL in cells. These observations suggest that in
the cellular environment, unlike in vitro, compound 142 alone may be not sufficient to disturb
SH3:linker interaction and stimulate ABL activity. However, when the regulatory interaction of
the myristoylated Ncap with the kinase domain C-lobe is perturbed by DPH, then the activat-
ing effect of SH3:linker displacement becomes readily apparent.
Summary and Conclusions
In this study, we developed a screening strategy to identify allosteric small molecule modula-
tors of ABL kinase activity that work outside of the kinase domain. Our FP-based assay targets
the regulatory domains of ABL that control its kinase activity through intramolecular interac-
tions. Specifically, this assay is based on a recombinant ABL protein comprising the complete
regulatory apparatus (Ncap-SH3-SH2-linker) and a synthetic polyproline probe peptide (p41)
that selectively binds the ABL SH3 domain. Interaction of the probe peptide with the ABL
N32L protein results in a robust and reproducible FP signal. Mutation of the SH3 binding site
Fig 12. Compound 142 cooperates with DPH to stimulate ABL core autophosphorylation in cells.Human embryonic kidney 293T cells were
transfected with an expression vector for the wild type ABL core followed by treatment with compound 142 overnight over the range of concentrations shown.
The experiment was performed in the absence or presence of the myristic acid binding pocket agonist DPH at a final concentration of 10 μM. ABL proteins
were immunoprecipitated from clarified cell lysates, and analyzed by immunoblotting with phosphospecific antibodies to three regulatory sites: pTyr412 in the
activation loop, pTyr89 in the SH3 domain, and pTyr245 in the SH2-kinase linker, as well as an ABL antibody to control for protein recovery. This experiment
was repeated twice with comparable results.
doi:10.1371/journal.pone.0133590.g012
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(W118A) or introduction of a high-affinity linker both resulted in loss of the FP signal, demon-
strating that probe access requires an intact and accessible SH3 domain. A small-scale pilot
screen of 1200 FDA-approved compounds identified dipyridamole (compound 142) as an
inhibitor of the FP signal observed with the N32L:p41 complex, and direct interaction of this
compound with the ABL N32L protein was confirmed by SPR and DSF assays. Dipyridamole
was observed to stimulate the kinase activity of downregulated ABL kinase in vitro, and was
more potent than the previously described ABL agonist DPH which targets the myristic acid
binding pocket in the kinase domain. In contrast to wild type ABL, dipyridamole had no effect
on a modified ABL core protein with a high-affinity linker, suggesting that it works by binding
to the SH3 domain and disrupting the SH3:linker interface. Molecular dynamics simulations in
combination with molecular docking support this proposed mechanism of action: dipyrida-
mole was predicted to interact with the ABL core through a pocket defined by the SH3:linker
interface. This interaction involved Trp118 on the SH3 domain binding surface, potentially
disrupting a key regulatory interaction with Pro249 in the linker. Discovery of dipyridamole as
an ABL agonist provides an important proof of concept that small molecules altering SH3:
linker interaction represent allosteric modulators of ABL kinase activity. Selective agonists of
ABL function have potential as chemical probes to better understand the role of ABL kinase
activity in solid tumors and in response to genotoxic stress. Conversely, allosteric antagonists
may also be discovered by this approach and have the potential to complement current ATP-
competitive inhibitors of BCR-ABL in the context of CML and other cancers. The allosteric
inhibitor discovery concept may also be extended to the discovery of allosteric modulators of
other kinases systems with multi-domain regulatory interactions, including members of the
SRC and TEC kinase families.
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